Medical emergency?Emergency? Call 911. Nearest emergency roomsNearest ERs

Prescription medicine

Asparaginase erwinia chrysanthemi (recombinant)-rywn

Drug class: Asparagine-specific Enzyme

The FDA’s “Established Pharmacologic Class”: the group of medicines that work in a similar way.

Official FDA data, not advice

Everything here comes from the U.S. Food and Drug Administration (FDA): the drug label, the NDC Directory, Drugs@FDA, recall reports and the drug shortage list. Each fact shows its source and date.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

In an emergency, call 911. If someone may have taken too much of a medicine, call Poison Help: 1‑800‑222‑1222.

Asparaginase erwinia chrysanthemi (recombinant)-rywn key facts

Drug class
Asparagine-specific Enzyme
Used for
RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. (source)
Prescription or over the counter
Prescription (Rx)
Generic available
No generic listed by the FDA
Latest FDA recall
None listed

Sources: FDA label (July 1, 2025); FDA NDC Directory (November 13, 2026); FDA enforcement reports (November 10, 2026). Not medical advice.

Quick answers

What is Asparaginase erwinia chrysanthemi (recombinant)-rywn used for?
The FDA-approved label (Rylaze, Jazz Pharmaceuticals, Inc., July 1, 2025) says: “RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
What are the side effects of Asparaginase erwinia chrysanthemi (recombinant)-rywn?
The “Adverse Reactions” section of the FDA label (Rylaze, Jazz Pharmaceuticals, Inc., July 1, 2025) begins: “The following clinically significant adverse reactions are described in greater detail in other sections of the labeling: • Hypersensitivity Reactions [see Warnings and Precautions (5.1)] • Pancreatic Toxicity [see Warnings and Precautions (5.2)] • Thrombosis [see Warnings and Precautions (5.3)] • Hemorrhage [see Warnings and Precautions (5.4)] • Hepatotoxicity, including VOD [see Warnings and Precautions (5.5)] Most common adverse reactions (incidence > 20%) are abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, and hypokalemia.” … This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Does Asparaginase erwinia chrysanthemi (recombinant)-rywn have a boxed warning?
No. None of the 1 FDA labels we found for this medicine has a boxed warning.
Is there a shortage of Asparaginase erwinia chrysanthemi (recombinant)-rywn?
No current shortage is listed by the FDA for the products of this medicine (FDA data from November 13, 2026).
Has Asparaginase erwinia chrysanthemi (recombinant)-rywn been recalled?
No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
Who makes Asparaginase erwinia chrysanthemi (recombinant)-rywn?
1 company lists prescription products of Asparaginase erwinia chrysanthemi (recombinant)-rywn in the FDA NDC Directory, including Jazz Pharmaceuticals, Inc.

What Asparaginase erwinia chrysanthemi (recombinant)-rywn is used for

Quoted from the “Indications and Usage” section of the FDA-approved label.

RYLAZE is indicated as a component of a multi-agent chemotherapeutic regimen for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adult and pediatric patients 1 month or older who have developed hypersensitivity to E. coli -derived asparaginase. …

— FDA label: Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025. Read the full label on DailyMed →

Label quoted: the one for the most common form (injection, intramuscular), Rylaze, Jazz Pharmaceuticals, Inc.; it covers 1 product in the FDA NDC Directory. The side effects, interactions, dosage and pregnancy quotes below come from this same label.

This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.

Conditions named on the label

These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.

Related medical specialties

Boxed warning

A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.

The label quoted above has no boxed warning.

Asparaginase erwinia chrysanthemi (recombinant)-rywn side effects

Quoted from the “Adverse Reactions” section of the FDA-approved label. Tell your doctor about any side effect that worries you.

The following clinically significant adverse reactions are described in greater detail in other sections of the labeling:

  • Hypersensitivity Reactions [see Warnings and Precautions (5.1)]
  • Pancreatic Toxicity [see Warnings and Precautions (5.2)]
  • Thrombosis [see Warnings and Precautions (5.3)]
  • Hemorrhage [see Warnings and Precautions (5.4)]
  • Hepatotoxicity, including VOD [see Warnings and Precautions (5.5)] Most common adverse reactions (incidence > 20%) are abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, and hypokalemia.
Read more of this section

(6.1) To report SUSPECTED ADVERSE REACTIONS, contact Jazz Pharmaceuticals Ireland Limited at 1-800-520-5568 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. The safety of RYLAZE described in the WARNINGS AND PRECAUTIONS reflect exposure in 167 patients administered RYLAZE intramuscularly at various dosages when used in combination with chemotherapy in study JZP458-201 [see Clinical Studies (14)]. These patients received a median of 4 courses of RYLAZE (range: 1-15 courses); 65% of patients received at least four courses. The safety of RYLAZE described below and in Table 3 was evaluated in study JZP458-201, a multi-cohort study. Patients received RYLAZE administered intramuscularly at dosages of 25 mg/m 2 on Monday, Wednesday, and Friday or 25 mg/m 2 on Monday and Wednesday, and 50 mg/m 2 on Friday, for 6 doses as a replacement for a single dose of pegaspargase as a component of multi-agent chemotherapy [see Clinical Studies (14)]. The patients had a median age of 11 years (range: 1‑25 years); the majority of patients were male (57%) and White (68%). The patients received a median of 4 courses of RYLAZE (range: 1-14 courses); 65% of patients received at least four courses. A fatal adverse reaction (infection) occurred in 1 patient treated with the RYLAZE 25/25/25 mg/m 2 dosage. Serious adverse reactions occurred in 60% of patients who received the recommended dosages of RYLAZE. The most frequent nonhematological serious adverse reactions (in ≥ 5% of patients) were febrile neutropenia, infection, drug hypersensitivity, pyrexia, nausea, dehydration, stomatitis, acute kidney injury, pancreatitis, diarrhea, and viral infection. Permanent discontinuation due to an adverse reaction occurred in 10% of patients who received RYLAZE intramuscularly at the recommended dosages. Adverse reactions resulting in permanent discontinuation included pancreatitis (5%), drug hypersensitivity (4%), and infection (1%). All patients treated with the recommended dosages of RYLAZE as a component of multi-agent chemotherapy experienced neutropenia, anemia, or thrombocytopenia. The most common nonhematological adverse reactions (incidence > 20%) in patients were abnormal liver test, nausea, musculoskeletal pain, infection, fatigue, headache, febrile neutropenia, pyrexia, hemorrhage, stomatitis, abdominal pain, decreased appetite, drug hypersensitivity, hyperglycemia, diarrhea, pancreatitis, and hypokalemia.

— FDA label: Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025. This is part of the section. Read the full label on DailyMed →

Asparaginase erwinia chrysanthemi (recombinant)-rywn dosage

Quoted from the “Dosage and Administration” section of the FDA-approved label. Your own dose is the one your doctor prescribes: do not change it on your own.

There are two RYLAZE regimens that can be used to replace a long-acting asparaginase product. The recommended dosages of RYLAZE are: When administered every 48 hours

  • 25 mg/m 2 intramuscularly every 48 hours; When administered Monday/Wednesday/Friday
  • 25 mg/m 2 intramuscularly on Monday morning and Wednesday morning and 50 mg/m 2 intramuscularly on Friday afternoon.
Read more of this section

(2.1) 2.1 Recommended Dosage There are two RYLAZE regimens that can be used to replace a long-acting asparaginase product. The recommended dosages of RYLAZE are: When administered every 48 hours:

  • 25 mg/m 2 administered intramuscularly every 48 hours; When administered on a Monday/Wednesday/Friday schedule:
  • 25 mg/m 2 intramuscularly on Monday morning and Wednesday morning, and 50 mg/m 2 intramuscularly on Friday afternoon. Administer the Friday afternoon dose 53 to 58 hours after the Wednesday morning dose (e.g., 8:00 am on Monday and Wednesday, and 1:00 pm to 6:00 pm on Friday) [see Clinical Pharmacology (12.3), Clinical Studies (14)]. Table 1 shows the number of RYLAZE dosages recommended for the intended duration of treatment for replacement of one dose of calaspargase pegol products (3 weeks of asparaginase coverage) or one dose of pegaspargase products (2 weeks of asparaginase coverage). See the full prescribing information for the long-acting asparaginase product to determine the total duration of administration of RYLAZE as replacement therapy. Table 1: Recommended Duration of RYLAZE Dosing to Replace One Long-Acting Asparaginase Dose When RYLAZE is Administered: Recommended Duration of RYLAZE to Replace Calaspargase Pegol Products Recommended Duration of RYLAZE to Replace Pegaspargase Products 25 mg/m 2 intramuscular every 48 hours Replace one dose of calaspargase pegol products with 11 doses of RYLAZE Replace one dose of pegaspargase products with 7 doses of RYLAZE 25 mg/m 2 intramuscular on Monday morning and Wednesday morning, and 50 mg/m 2 intramuscular on Friday afternoon* Replace one dose of calaspargase pegol products with 9 doses of RYLAZE Replace one dose of pegaspargase products with 6 doses of RYLAZE *See bullet above for timing of 25/25/50 mg/m 2 dosing of RYLAZE. 2.2 Recommended Premedication Premedicate patients with acetaminophen, an H-1 receptor blocker (such as diphenhydramine), and an H-2 receptor blocker (such as famotidine) 30-60 minutes prior to administration of RYLAZE to decrease the risk and severity of hypersensitivity reactions [see Warnings and Precautions (5.1)]. 2.3 Recommended Monitoring and Dosage Modifications for Adverse Reactions Monitor patient’s bilirubin, transaminases, glucose, and clinical examinations prior to treatment every 2-3 weeks and as indicated clinically. If results are abnormal, monitor patients until recovery from the cycle of therapy. If an adverse reaction occurs, modify treatment according to Table 2. Table 2: Dosage Modifications Adverse Reaction Severity* Action Hypersensitivity Reaction [see Warnings and Precautions (5.1)] Grade 2
  • Treat the symptoms. Grade 3 to 4
  • Discontinue RYLAZE permanently.
Table from the label
When RYLAZE is Administered:Recommended Duration of RYLAZE to Replace Calaspargase Pegol ProductsRecommended Duration of RYLAZE to Replace Pegaspargase Products
25 mg/m2 intramuscular every 48 hoursReplace one dose of calaspargase pegol products with 11 doses of RYLAZEReplace one dose of pegaspargase products with 7 doses of RYLAZE
25 mg/m2 intramuscular on Monday morning and Wednesday morning, and 50 mg/m2 intramuscular on Friday afternoon*Replace one dose of calaspargase pegol products with 9 doses of RYLAZEReplace one dose of pegaspargase products with 6 doses of RYLAZE

— FDA label: Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025. This is part of the section. Read the full label on DailyMed →

Asparaginase erwinia chrysanthemi (recombinant)-rywn in pregnancy

Quoted from the pregnancy part of the FDA-approved label. Ask your doctor before you take any medicine while pregnant or planning a pregnancy.

Risk Summary Based on findings from animal reproduction studies, RYLAZE can cause fetal harm when administered to a pregnant woman. There are no available data on RYLAZE use in pregnant women to evaluate for a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.

Read more of this section

In animal reproductive and developmental toxicity studies, intramuscular administration of asparaginase Erwinia chrysanthemi to pregnant rats and rabbits during organogenesis resulted in structural abnormalities and embryo-fetal mortality (see Data) at exposures below those in patients at the recommended human dose. Advise pregnant women of the potential risk to a fetus. In the U.S. general population, the estimated background risks of major birth defects and miscarriage in clinically recognized pregnancies are 2 to 4% and 15 to 20%, respectively. Data Animal Data Animal reproductive and developmental toxicity studies have not been conducted with RYLAZE. In embryofetal development studies, asparaginase Erwinia chrysanthemi was administered intramuscularly every other day during the period of organogenesis to pregnant rats (at 3, 6, or 12 mg/m 2) and rabbits (at 0.12, 0.30, or 0.48 mg/m 2). In rats given 12 mg/m 2 (approximately 0.48 times the maximum recommended human dose), maternal toxicity of decreased body weight gain was observed, as was a fetal finding of increased incidence of partially undescended thymic tissue. In rabbits, maternal toxicity consisting of decreased body weight was observed at 0.48 mg/m 2 (approximately 0.02 times the maximum recommended human dose). Increased post-implantation loss, a decrease in the number of live fetuses, and gross abnormalities (e.g., absent kidney, absent accessory lung lobe, additional subclavian artery, and delayed ossification) were observed at doses of ≥ 0.12 mg/m 2 (approximately 0.005 times the maximum recommended human dose).

— FDA label: Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025. Read the full label on DailyMed →

When Asparaginase erwinia chrysanthemi (recombinant)-rywn should not be used

Quoted from the “Contraindications” section of the FDA-approved label.

RYLAZE is contraindicated in patients with:

  • History of serious hypersensitivity reactions to Erwinia asparaginase, including anaphylaxis [see Warnings and Precautions (5.1)];
  • History of serious pancreatitis during previous asparaginase therapy [see Warnings and Precautions (5.2)];
  • History of serious thrombosis during previous asparaginase therapy [see Warnings and Precautions (5.3)];
  • History of serious hemorrhagic events during previous asparaginase therapy [see Warnings and Precautions (5.4)];
  • Severe hepatic impairment [see Warnings and Precautions (5.5)].
Read more of this section

RYLAZE is contraindicated in patients with:

  • History of serious hypersensitivity reactions to RYLAZE, including anaphylaxis. (4)
  • History of serious pancreatitis during previous L-asparaginase therapy. (4)
  • History of serious thrombosis during previous L-asparaginase therapy. (4)
  • History of serious hemorrhagic events during previous L-asparaginase therapy. (4)
  • Severe hepatic impairment. (4)

— FDA label: Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025. Read the full label on DailyMed →

Forms and how it is given

Dosage formsInjection
RouteIntramuscular
Prescription products1 in the FDA NDC Directory
Brand namesRylaze

Companies that list this medicine

Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.

FDA approval history

  • BLA: Biologics License Application: how a biologic medicine (made from living cells) is approved.
Brand and biologic applications
ApplicationSponsorApprovedLater changes approved
BLA761179
RYLAZE
Jazz PharmsJune 30, 2021 3, latest April 15, 2024
2024: Labeling · 2022: Efficacy · 2021: Labeling

Shortage status

The FDA drug shortage list does not show these products.

FDA Drug Shortages database →

Recalls

No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.

Official identifiers

RxCUI (RxNorm)2561251, 2561256
SPL set ID of the quoted label857e53aa-1098-4dad-b654-0276cdd43e03
FDA labels (SPL)1
FDA applicationsBLA761179
Active ingredients (FDA)ASPARAGINASE

Next steps

Sources

  1. FDA-approved label on DailyMed (National Library of Medicine) — Rylaze, Jazz Pharmaceuticals, Inc., effective July 1, 2025; via openFDA, FDA data exported November 13, 2026, retrieved November 14, 2026
  2. NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  3. Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026
  4. Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 10, 2026, retrieved November 14, 2026
  5. Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported November 13, 2026, retrieved November 14, 2026

openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →

Report an error → · Information for medicine makers